SpineX

[Image from SpineX]SpineX announced today that its first-in-human study backs the use of its proprietary non-surgical treatment for children with cerebral palsy (CP).

Los Angeles-based SpineX published the study in Nature Communications. Dr. Susan Hastings and Dr. V Reggie Edgerton led the study.

SCiP demonstrated unparalleled functional improvements with SCiP (spinal cord innovation in pediatrics) in children with CP. The study combined non-invasive spinal neuromodulation and activity-based neurorehabilitation therapy, SpineX said in a news release.

SpineX said SCiP delivery during physical therapy improved sensorimotor function in 16 of 16 children. This patient population included a wide range of ages and CP severity. The treatment holds breakthrough device designation from the FDA. The company plans to align with the agency for a proposed clinical trial for 2023. It plans to use the results to pursue FDA clearance for SCiP in the treatment of CP.

Read more

[Image from SpineX]SpineX announced today that it enrolled the first patient in its pivotal trial evaluating the Scone neuromodulation device.

Los Angeles-based SpineX will evaluate the safety and effectiveness of the non-invasive spinal neuromodulation technology for the treatment of neurogenic bladder.

The first patient was enrolled at the Rancho Research Institute of the Rancho Los Amigos National Neurorehabilitation Center in Downey, California, according to a news release.

SpineX designed Scone therapy to treat symptoms such as the lost sensation of bladder fullness, low bladder capacity, frequent urination cycles during both day and night and living with constant fear of uncontrolled urine leakage.

Dr. Evgeniy Kreydin, the company’s co-founder and assistant professor at the University of Southern California, Los Angeles, said in the release that while the inability to walk is the most obvious functional loss for a person in a wheelchair, …